1. General principles of psychopharmacological treatment --
Legal, ethical, and economic issues --
2. Diagnosis and classifiction --
Schizophrenia and other schizophrenia spectrum disorders --
Psychoactive substance use disorders --
Child and adolescent disorders --
FDA approval of symptom reduction strategies --
DSM-V and pharmacogenetics --
General priciples of antidepressant use --
Choosing an antidepressant --
Dosage and administration --
Selective serotonin reuptake inhibitors --
Pharmacological effects --
Dosage and administration --
5-HT₂ receptor antagonists (Trazodone and Nefazodone) --
Pharmacological effects --
Dosage and admdinistratin --
Selective serotonin-norepinephrine reuptake inhibitors (Venlafaxine and Duloxetine) --
Pharmacological effects --
Dosage and administration --
Combined noradrenergic-dopaminergic antidepressant (Bupropion) --
Pharmacological effects --
Dosage and administration --
Pharmacological effects --
Dosage and administration --
Norepinephrine reuptake inhibitors : reboxetine and atomoxetine --
Pharmacological effects --
Dosage and administration --
Tricyclic and tetracyclic antidepressants --
Pharmacological effects --
Dosage and administration --
Monoamine oxidase inhibitors --
Pharmacological effects --
Dosage and administration --
Selective and reversible monoamine oxidase inhibitors --
Melatonin agonist-5-HT₂c antagonist --
4. Antipsychotic drugs --
General principles of antipsychotic use --
Acute antipsychotic treatment --
Early inpatient treatment --
Maintenance drug therapy --
Use in other psychiatric disorders --
Atypical antipsychotics --
Standard (typical) antipsychotics --
Other options for treating negative symptoms --
Alternatives to antipsychotic therapy --
Antipsychotic drugs in development --
History and indications --
Pharmacological effects --
Dosage and administration --
Lithium Information Center --
Calcium channel blockers --
Pharmacological effects --
Dosage and administration --
Generalized anxiety disorder --
Body dysmorphic disorder --
Posttraumatic stress disorder --
Obsessive-compulsive disorder --
Dosage and administration --
Amobarbital sodium (amytal) as a parenteral solution --
Pharmacological approaches --
Benzodiazephine hypnotics --
Nonbenzodiazephine hypnotics --
Melatonin receptor agonist : Remelteon --
Sedative antihistamines and other nonbenzodiazepine psychoactive drugs with hypnotic properties --
Nonbarbiturate hypnotics --
Over-the-counter sleeping agents --
8. Stimulants and other fast-acting drugs --
Attention-deficit/hyperactivity disorder --
Acquired immunodeficiency syndrome --
Other medical conditions --
Stimulant use versus abuse --
Other fast-acting drugs --
9. Augmentation strategies for treatment-resistant disorders --
Augmentation strategies for depression --
Lithium-antidepressant combinations --
Thyroid supplement-antidepressant combinations --
Estrogen, DHEA, and testosterone combinations with antidepressants --
Dopamine agonist-antidepressant combinations --
Monoamine precursor-antidepressant combinations --
Antipsychotic-antidepressant combinations --
Other TCA combinations --
Augmentation strategies for bipolar disorder --
Combinations of two or more mood stabilizers --
Mood stabilizer-antipsychotic combinations --
Mood stabilizer-antidepressant combinations --
Mood stabilizers and omega-3 fatty acids --
Augmentation strategies for schizophrenia --
Combinations of two antipsychotics --
Combinations of antidepressants and antipsychotics --
Combinations of mood stabilizers and antipsychotics --
Other augmentation strategies --
10. Emergency room treatment --
Agitation and violence --
Depression and suicidality --
Acute psychotic reactions --
Mixed psychotic reactions --
Schizophrenic, schizophreniform, and manic psychoses --
Emergency room referrals --
11. Pharmacotherapy for substance use disorders --
Sedatives and hypnotics --
Pentobarbital tolerance test --
12. Pharmacotherapy in special situations --
Pediatric psychopharmacology --
Geriatric psychopharmacology --
Hypnotics and anxiolytics --
Medications for dementia --
Medications for agitation --
Psychiatric disorders resulting from medical illness --
Psychiatric disorders associated with nonpsychiatric drugs --
Psychiatric disorders complicated by medical disorders --
13. Herbals and dietary supplements --
St. John's Wort (Hypericum perforatum) --
Side effects and drug interactions --
Dosage and administration --
Uses and mechanism of action --
Side effects and drug interactions --
Dosage and administration --
Kava (Piper methysticum) --
Side effects and drug interactions --
Dosage and administration --
Valerian (Valeriana officinalis) --
Side effects and drug interactions --
Dosage and administration --
Ginkgo (Ginkgo biloba) --
Side effects and drug interactions --
Dosage and administration --
S-adenosylmethionine (SAMe) --
Side effects and drug interactions --
Dosage and administration --
Side effects and drug interactions --
Dosage and administration.
DHEA (dehydroepiandrosterone) --
Side effects and drug interactions --
Dosage and administration --
Appendix A : Strengths and costs of antidepressant and antipsychotic drugs --
Appendix B : Suggested readings --
